stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Return on equity
Xeris Biopharma Holdings, Inc.'s return on equity over the twelve months to 30 September 2026 was −27.1%, down 20.2 percentage points from fiscal 2025 (−6.96%). Over the past ten years it has ranged from −683.7% (fiscal 2018) to 301.3% (fiscal 2024); the current reading is higher than 70% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and in line with the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −6.96% | (308.28) |
| FY2024 | 301.3% | 625.52 |
| FY2023 | −324.2% | (189.37) |
| FY2022 | −134.8% | 55.45 |
| FY2021 | −190.3% | 187.92 |
| FY2020 | −378.2% | (98.64) |
| FY2019 | −279.6% | 404.10 |
| FY2018 | −683.7% | (742.82) |
| FY2017 | 59.2% | 29.73 |
| FY2016 | 29.4% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 91.6% |
| PBH Prestige Consumer Healthcare Inc. compare | 8.23% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. | −27.1% |
| TRLV Trulieve Cannabis Corp. compare | −45.5% |
| PRGO Perrigo Company plc compare | −51.4% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −74.7% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement